Archive


Category: Biomarker-Guided Drug Development

  • GrayMatters Health Raises $10M for Biomarker-Based PTSD Therapeutics

    What You Should Know: – GrayMatters Health (GMH), a company set to change the standards of mental health care with biomarker-based therapeutics, beginning with PTSD raises $10 million in Series A funding round led by Otsuka Medical Devices Co., Ltd., bringing total funding to $13.5 million. Additional investors in the Series A round included Joy Ventures, J-Ventures, and J-Impact. Existing GMH investors, Marius Nacht […]